Collegium Pharmaceutical (COLL) Announces 2026 Financial Guidance and Business Update
Stoughton, Mass., January 08, 2026 – Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has released its financial guidance for 2026, projecting a robust start to the year following a record-breaking 2025.
Key Financial Highlights for 2026
- Expected Product Revenues: Between $805 million and $825 million
- Projected Jornay PM® Revenue: Anticipated to be in the range of $190 million to $200 million
- Adjusted EBITDA: Forecasted between $455 million and $475 million
Executive Insights on 2025 Performance
“2025 was a year of record growth for Collegium, and we are excited to begin 2026 with significant momentum for continued success,” stated Vikram Karnani, President and CEO of Collegium Pharmaceutical. He emphasized the company's strong financial position attributed to the exceptional performance of Jornay PM and sustained revenue growth in their pain management portfolio.
Colleen Tupper, CFO, noted, “We are on track to achieve our recently increased financial guidance for 2025. We expect continued topline revenue growth in 2026, significantly driven by increasing sales of Jornay PM.” She added that the company is keen on executing its capital deployment strategy to balance debt repayment and share repurchase opportunities.
Recent Business Developments
Collegium has achieved several pivotal milestones:
- Raised its financial guidance for full-year 2025 to a net revenue range of $775 million to $785 million.
- Closed a $980 million syndicated credit facility, repaying the remaining balance of a previous term loan.
- Established supply agreements with Hikma Pharmaceuticals USA Inc. for authorized generic versions of Nucynta® and Nucynta® ER.
These agreements are expected to enhance revenue streams, with Hikma launching Nucynta ER in Q1 2026.
Looking Ahead: Financial Guidance for 2026
Collegium's 2026 financial guidance underlines the company’s growth trajectory:
- Net product revenues are projected to be between $805 million and $825 million.
- Jornay PM revenue is expected within the range of $190 million to $200 million.
- Adjusted EBITDA is targeted between $455 million and $475 million.
This outlook reflects Collegium’s commitment to growing its commercial operations while supporting patients with serious medical conditions.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is dedicated to enhancing the quality of life for individuals with serious health conditions. The company specializes in responsible pain management medications and has a rapidly expanding neuropsychiatry business, with Jornay PM as a premier product driving its growth. Based in Stoughton, Massachusetts, Collegium is focused on disciplined capital management and strategic advancements.
For additional information, please visit www.collegiumpharma.com.
Understanding Non-GAAP Financial Measures
Collegium utilizes non-GAAP measures, like adjusted EBITDA, to provide deeper insights into operational performance. Adjusted EBITDA represents GAAP net income adjusted for various factors that influence ongoing operations but are not directly indicative of the company's financial commitments.
While adjusted EBITDA provides useful insight, it is essential to recognize that it excludes vital expenses such as depreciation, amortization, and changes in working capital. As such, it may not offer a complete picture of financial health compared to traditional GAAP metrics.